Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers

Zika virus (ZIKV) is an emerging mosquito-borne flavivirus that has spread to more than 70 countries worldwide since 2015. Despite active research, there are currently no licensed vaccines or therapeutics. We have previously reported the development of various adenoviral vectored vaccine candidates...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	López-Camacho, C, Kim, Y, Abbink, P, Larocca, R, Huiskonen, J, Barouch, D, Reyes-Sandoval, A
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	MDPI 2019

Gelijkaardige items

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
door: César López-Camacho, et al.
Gepubliceerd in: (2019-11-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
door: Moorthy, V, et al.
Gepubliceerd in: (2003)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
door: Alharbi, N
Gepubliceerd in: (2014)

Clinical development of Modified Vaccinia virus Ankara vaccines.
door: Gilbert, S
Gepubliceerd in: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines
door: Gilbert, S
Gepubliceerd in: (2013)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
door: McConkey, S, et al.
Gepubliceerd in: (2003)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
door: Rosario, M, et al.
Gepubliceerd in: (2010)

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara.
door: Schneider, J, et al.
Gepubliceerd in: (1998)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
door: L. F. Stovba, et al.
Gepubliceerd in: (2023-04-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
door: Olga Vladimirovna Orlova, et al.
Gepubliceerd in: (2022-09-01)

Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara
door: Nereida Jiménez de Oya, et al.
Gepubliceerd in: (2022-03-01)

Immunogenicity and efficacy of Zika virus envelope domain III in DNA, protein, and ChAdOx1 adenoviral-vectored vaccines
door: López-Camacho, C, et al.
Gepubliceerd in: (2020)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
door: Alharbi, N, et al.
Gepubliceerd in: (2015)

Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.
door: Naif Khalaf Alharbi, et al.
Gepubliceerd in: (2015-01-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
door: Lior Nave, et al.
Gepubliceerd in: (2023-08-01)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
door: Kaïdre Bendjama, et al.
Gepubliceerd in: (2017-09-01)

Phase 2a safety and immunogenicity testing of DNA and recombinant modified vaccinia ankara virus vaccines expressing virus-like particles
door: Goepfert P, et al.
Gepubliceerd in: (2012-09-01)

Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-vectored Ebola vaccines: a randomized clinical trial
door: Milligan, I, et al.
Gepubliceerd in: (2016)

Immunogenicity and reactogenicity of novel adenovirus type 26 and modified vaccinia Ankara-vectored Ebola vaccines: A randomized clinical trial
door: Milligan, I, et al.
Gepubliceerd in: (2016)

Enhanced immunogenicity of CD4(+) t-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.
door: Mcshane, H, et al.
Gepubliceerd in: (2001)

Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction.
door: Behboudi, S, et al.
Gepubliceerd in: (2004)

Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
door: César López-Camacho, et al.
Gepubliceerd in: (2020-06-01)

Reactogenicity and Immunogenicity Against MPXV of the Intradermal Administration of Modified Vaccinia Ankara Compared to the Standard Subcutaneous Route
door: Valentina Mazzotta, et al.
Gepubliceerd in: (2024-12-01)

Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
door: Goonetilleke, N, et al.
Gepubliceerd in: (2003)

The third generation modified vaccinia Ankara vaccine is effective in preventing the transmission of mpox
door: Mingwang Shen, et al.
Gepubliceerd in: (2024-10-01)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
door: Gilbert, S, et al.
Gepubliceerd in: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
door: Juan García-Arriaza, et al.
Gepubliceerd in: (2021-08-01)

Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidate.
door: Jeffrey R Currier, et al.
Gepubliceerd in: (2010-11-01)

Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.
door: Sandhya Vasan, et al.
Gepubliceerd in: (2010-01-01)

Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
door: Hanke, T, et al.
Gepubliceerd in: (1998)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
door: Howles, S, et al.
Gepubliceerd in: (2010)

Improved Host Range Selection for Recombinant Modified Vaccinia Virus Ankara
door: Caroline Staib, et al.
Gepubliceerd in: (2003-04-01)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
door: Volker Sandig, et al.
Gepubliceerd in: (2013-11-01)

Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
door: Leonie Mayer, et al.
Gepubliceerd in: (2024-11-01)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
door: Flavia Chiuppesi, et al.
Gepubliceerd in: (2024-02-01)

The Efficacy of Disinfection on Modified Vaccinia Ankara and African Swine Fever Virus in Various Forest Soil Types
door: Franziska Tanneberger, et al.
Gepubliceerd in: (2021-10-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
door: Harriet L. Robinson, et al.
Gepubliceerd in: (2018-09-01)

Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
door: David A Garber, et al.
Gepubliceerd in: (2009-01-01)

Correction: Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates
door: Leonie Mayer, et al.
Gepubliceerd in: (2024-12-01)

Transient Host Range Selection for Genetic Engineering of Modified Vaccinia Virus Ankara
door: C. Staib, et al.
Gepubliceerd in: (2000-06-01)